Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIO Good information. My son will appreciate it. Thanks!
Thanks for the feedback. I passed it along. He is holding for the long picture.
North Thanks anyway. My son has a position in ACHN and was asking me the same question. I had the same answer.
BIO Bad news bears for those folks.
North do you see a steady rise in PPS on ACHN?
Aprilov. Whatever Zacks PR'S I have always done the opposite. It works.
PPHMownsme
I was being a bit sarcastic here. Of coarse they have many irons in the fire as a they approach SUNRISE approval status. I think our deal will be much better then what was on the table back then with Abbvie. I think their business card may not be needed.
PPHMownsMe Any chance they left their business card behind with PPHM for future considerations. Presuming SUNRISE approval of coarse. Or do you think with their recent deal with PCYC they are out of the picture?
Threes FDA approved SUNRISE with Avid in full production coupled with generic Doce. PPHM will be one being resurrected and cost will be reduced for roll out.
There are numerous players with NSCLC trials. Doce reign is in jeopardy.
Who wants to stop Sunrise so Doce can't improve on it's results.
They pretty much know Doce alone is done.
If Bavi does not resurrect it with blow out numbers they are toast.
PPHMownsMe Any chance they left their business card behind with PPHM for future considerations. Presuming SUNRISE approval of coarse. Or do you think with their recent deal with PCYC they are out of the picture?
Well, let's see... it's been over 2.5 years since Abbvie walked away from the first potential partnership, the stock is currently valued at less than 1/3 of what is was at the time while the # of outstanding shares has gone up significantly...
HYPI We on opposite tracks for the moment I increased my shares again from 107500 to 125,000. I like our chances. GLTU
I lowered my position for 50K to 25K
Only been invested a few years in PPHM but I expect FDA approval. GL
Yes the up coming weeks and months should be promising.
BUGS has walked off with all the carrots. Hope he brings a few back.
Peregrine Pharmaceuticals' Immuno-Oncology Agent Bavituximab to be Highlighted in Three Presentations at 2015 ASCO Annual Meeting
TUSTIN, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (PPHM) (PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced the presentation of three posters at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29-June 2, 2015 in Chicago, Illinois.
Abstract: 3059
Title: Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer
Presenter: Xianming Huang, Ph.D., The University of Texas Southwestern Medical Center
Session: Developmental Therapeutics—Immunotherapy
Track(s): Developmental Therapeutics and Translational Research
Session Type: General Poster Session
Time and Location: Saturday, May 30 8:00 AM - 11:30 AM CDT, S Hall A
Abstract: 3060
Title: Activation of CD8+ tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients
Presenter: Soner Altiok, M.D, Ph.D., H. Lee Moffitt Cancer Center & Research Institute
Session: Developmental Therapeutics—Immunotherapy
Track(s): Developmental Therapeutics and Translational Research
Session Type: General Poster Session
Time and Location: Saturday, May 30 8:00 AM - 11:30 AM CDT, S Hall A
Abstract: 4109
Title: A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
Presenter: Adam Charles Yopp, M.D., The University of Texas Southwestern Medical Center
Session: Gastrointestinal (Noncolorectal) Cancer
Track(s): Gastrointestinal (Noncolorectal) Cancer
Session Type: General Poster Session
Time and Location: Monday, Jun 1 8:00 AM - 11:30 AM CDT, S Hall A
In addition, Peregrine will be hosting ASCO conference attendees at booth #22107.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.
Contact:
Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
KENNETH B. DART
Mr. Dart is the beneficial owner of all of the outstanding shares of Portfolio Services Ltd., which in turns owns all the outstanding shares of Eastern Capital Limited.
SHARED DISPOSITIVE POWER
9,921,760
checked list no I am not.
Total 91 Institutional Shares 30,198,455
You can google Earth or call to confirm I would suppose. Joking!
PPHM & Avid
Others pursuing manufacturing facilities for their immune therapies.
Bellicum buys into CAR-T manufacturing amid a hot immuno-oncology race.
Following the lead of Juno Therapeutics and Kite Pharma, CAR-T contender Bellicum Pharmaceuticals ($BLCM) is splashing cash on an in-house manufacturing operation, speeding its cell therapies into clinical trials in a host of cancers.
The biotech has leased a 27,000-square-foot manufacturing site that can churn out the modified T cells needed for so-called CAR-T therapies, which soup up patients' immune systems to fight cancer. The new facility will sit on Bellicum's Houston campus, adjacent to the Texas Medical Center, the company said.
CAR-T rivals Juno ($JUNO) and Kite ($KITE) each made similar splashes on manufacturing this year, believing that the complex process of crafting cell therapies is best done internally and not left to contractors. Novartis ($NVS), a leader in the space, has built dedicated facilities of its own, and each company is pursuing a fleet of clinical trials in hopes of establishing CAR-T's promise in more and more indications.
ebo783 I like our chances. GLTU
Will see. I generally do quite well with the speculative investments
in my portfolio.
IFU you make some good points. Obviously, my investments are more reasoned then that. Perhaps attackers was the wrong characterization. This is one of many stocks I am invested in and somehow this one intrigues me for it potential. Will see how this one ends up. GL
The more attacks on Peregrine the more convinced I get we have
value. Noticed longs are adding more shares in the face of this.
Holding for SUNRISE results and other trials.
P-value considerations
Statistical significance plays a pivotal role in statistical hypothesis testing, where it is used to determine whether a null hypothesis should be rejected or retained. A null hypothesis is the general or default statement that nothing happened or changed.[21] For a null hypothesis to be rejected as false, the result has to be identified as being statistically significant, i.e. unlikely to have occurred due to sampling error alone.
To determine whether a result is statistically significant, a researcher would have to calculate a p-value, which is the probability of observing an effect given that the null hypothesis is true.[7] The null hypothesis is rejected if the p-value is less than the significance or a level. The a level is the probability of rejecting the null hypothesis given that it is true (type I error) and is most often set at 0.05 (5%). If the a level is 0.05, then the conditional probability of a type I error, given that the null hypothesis is true, is 5%.[22] Then a statistically significant result is one in which the observed p-value is less than 5%, which is formally written as p < 0.05.[22]
If an observed p-value is not lower than the significance level, then rather than simply accepting the null hypothesis, where feasible it would often appear to be appropriate to increase the sample size of the study, and see whether the significance level is then reached.[23] Nevertheless, the practice of increasing the number of subjects may result in the smallest effect having statistical significance. [24] In these cases, reporting effect sizes becomes particularly important.
If the a level is set at 0.05, it means that the rejection region comprises 5% of the sampling distribution.[25] These 5% can be allocated to one side of the sampling distribution, as in a one-tailed test, or partitioned to both sides of the distribution as in a two-tailed test, with each tail (or rejection region) containing 2.5% of the distribution. One-tailed tests are more powerful than two-tailed tests, as a null hypothesis can be
rejected with a less extreme result.
http://en.wikipedia.org/wiki/Statistical_significance
Google translate will have to do. Only know a few German words. Thanks
Yes it appears to be the case. Curious if Abbvie is still in the picture monitoring developments.
TOG sure would be a good time to change up on that. GLTA
Would be a very nice development Crossing fingers! Both hands!
Ok IF options not exercised what is the most likely rational.
Anyone? Pending Partnership announcement or deal. Is that it?
AF had a big short POS back then.
Profile emerges when approved and licensed.
CP thanks I can stop scratching my head now. Figured a response was in the works.
Glad to MD. Enjoy your day.
From this PR link on P2 I draw my attention to what was in the works. Should be well established for SUNRISE.
"Robust data from this Phase II trial clearly demonstrate a significant benefit in overall survival with a good safety profile in patients receiving bavituximab plus docetaxel compared to those receiving docetaxel plus placebo," said Steven W. King, president and chief executive officer of Peregrine. "We are currently in discussions with several potential pharmaceutical partners who have expressed great interest in our bavituximab oncology program. It is our goal to identify the optimal partner to assist with the design and logistics of a multinational Phase III pivotal trial."
OK IFU fair point. Hopefully more articles will come out related to our antibody and PS. That would be encouraging.
IFU
Lots of BIO articles on immunotherapy that mention Paradigm shift.
Check Fierce Biotech among many sources. Kinda think you know this.
Even this article indicates it somewhat.
Recent clinical data suggest that combination immunotherapy may be the wave of the future. To capitalize on these exciting findings, the scientific, logistical, proprietary and financial hurdles to the clinical testing of combination therapy must be addressed.
CB I should add with Dr. Garnik's background and experience I am sure he will know how to navigate in the trenches with the FDA to innumerate on what you state below.
This is where Garnick needs to earn his fees and use his experience and contacts in fda.
CB points taken but I still like our chances of FDA approval. IMO
CB Dr. Garnick stated OS would be crystal clear upon SUNRISE completion. That was a confident statement. Not my opinion his thoughts. Of course your thoughts and opinions are respected.
CP in valuable to this board. Thanks as always.